FDA Panel Gives Nod To Long-Acting Form Of Lilly’s Schizophrenia Drug Zyprexa
This article was originally published in The Pink Sheet Daily
Executive Summary
With appropriate label warnings, the excessive sedation side effect should not preclude approval of the atypical antipsychotic’s depot formulation.